Palatin Technologies, Inc.
A biopharmaceutical company that develops medicines working on the body's melanocortin receptor system, Palatin Technologies is headquartered in Princeton, New Jersey. Its most visible product is Vyleesi, an FDA-approved injectable treatment for low sexual desire in premenopausal women, delivered through a self-administered autoinjector. Founded in 1986 by Carl Spana and John K.A. Prendergast, the company also develops treatments for obesity and rare metabolic disorders.
Sold 1.14M
Sold 2.70M
Granted 319.5K
Granted 550.0K
Granted 65.0K · Bought 10.0K
Granted 511.5K · Bought 214.5K · Sold 65.7K
Granted 7.64M · Bought 216.5K
Granted 6.99M · Bought 216.5K · Sold 10.6K
Granted 511.5K · Bought 17.3K
Granted 466.5K · Bought 45.0K
Granted 374.0K
Granted 503.5K · Bought 39.1K · Sold 1.4K
Granted 887.6K
Bought 10.0K
Bought 5.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Biotechnology Value Fund II LP +5 co-filersSee Explanation of Responses, 10% owner · 19 transactions | — | 3.71Mas of Feb 2014 | — | — | 1.14M |
| Marxe Austin W & Greenhouse David M10% owner · 1 transaction | — | 1.80Mas of Oct 2011 | — | — | 2.70M |
| Rossetti AngelaDirector · 9 transactions | — | 503.6Kas of Jun 2020 | 319.5K | — | — |
| Hallam TrevorExec VP - Research & Dev · 4 transactions | — | 478.9Kas of Mar 2010 | 550.0K | — | — |
| Horovitz Zola PDirector · 3 transactions | — | 250.7Kas of Dec 2015 | 65.0K | 10.0K | — |
| Deveer Robert K JrDirector · 28 transactions | — | 138.1Kas of May 2025 | 511.5K | 214.5K | 65.7K |
| Spana CarlPresident and CEO, Director · 117 transactions | — | 64.4K | 7.64M | 216.5K | — |
| Wills Stephen TExecutive VP and CFO/COO · 125 transactions | — | 63.4K | 6.99M | 216.5K | 10.6K |
| Hull Joseph StanleyDirector · 18 transactions | — | 42.3Kas of Jul 2024 | 511.5K | 17.3K | — |
| Morris ArleneDirector · 18 transactions | — | 41.6Kas of Jul 2024 | 466.5K | 45.0K | — |
| Manning Anthony M.Director · 9 transactions | — | 36.1Kas of Jul 2024 | 374.0K | — | — |
| Dunton Alan WDirector · 35 transactions | — | 14.1K | 503.5K | 39.1K | 1.4K |
| Prendergast John K ADirector · 15 transactions | — | 13.8K | 887.6K | — | — |
| Molinoff Perry BDirector · 1 transaction | — | 11.0Kas of Dec 2012 | — | 10.0K | — |
| Taber Robert IDirector · 1 transaction | — | 5.5Kas of Jan 2013 | — | 5.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -3.14M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.